Trial Profile
Randomised Clinical Trial of Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Guanfacine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NorAD
- 01 Aug 2022 Trial design and study protocol published in the Trials
- 17 Feb 2021 Status changed from suspended to recruiting.
- 17 Feb 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2022.